{"filing":{"accession_number":"0001193125-26-269549","cik":"0001813814","ticker":"DFTX","company_name":"Definium Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-12","report_date":null,"primary_document":"dftx-20260611.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526269549/dftx-20260611.htm"},"events":[{"id":10283,"run_id":9018,"accession_number":"0001193125-26-269549","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Definium Therapeutics held its Annual Meeting on June 11, 2026, with shareholders voting on and approving the election of seven directors, the appointment of KPMG LLP as auditor, and an amendment to the 2025 Equity Incentive Plan increasing available shares by 5,000,000.","company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","filing_date":"2026-06-12","form":"8-K","submitted_at":null,"items":[{"id":6563,"accession_number":"0001193125-26-269549","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on shareholder approval of an amendment to the 2025 Equity Incentive Plan increasing available shares by 5,000,000 for issuance under the plan. This is a compensatory arrangement disclosure under Item 5.02(e), as equity plan amendments directly affect the pool of securities available for executive and employee compensation. The materiality is evident from the substantial increase in authorized shares and the formal shareholder vote required.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:00:42.717822+00:00","company_name":"","ticker":null,"filing_date":""},{"id":6564,"accession_number":"0001193125-26-269549","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure presents the final voting results from Definium Therapeutics' June 11, 2026 Annual Meeting, including election of seven directors, appointment of KPMG LLP as auditor, and approval of an Equity Plan Amendment. The filing directly matches the shareholder_vote_results event type, which covers results of votes at annual or special meetings of security holders. The disclosure is material as it confirms governance outcomes and capital allocation decisions affecting shareholders.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:00:42.717822+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6563,"accession_number":"0001193125-26-269549","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on shareholder approval of an amendment to the 2025 Equity Incentive Plan increasing available shares by 5,000,000 for issuance under the plan. This is a compensatory arrangement disclosure under Item 5.02(e), as equity plan amendments directly affect the pool of securities available for executive and employee compensation. The materiality is evident from the substantial increase in authorized shares and the formal shareholder vote required.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:00:42.717822+00:00","company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","filing_date":"2026-06-12"},{"id":6564,"accession_number":"0001193125-26-269549","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure presents the final voting results from Definium Therapeutics' June 11, 2026 Annual Meeting, including election of seven directors, appointment of KPMG LLP as auditor, and approval of an Equity Plan Amendment. The filing directly matches the shareholder_vote_results event type, which covers results of votes at annual or special meetings of security holders. The disclosure is material as it confirms governance outcomes and capital allocation decisions affecting shareholders.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:00:42.717822+00:00","company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","filing_date":"2026-06-12"}]}